NKX-019

Nkarta has initiated enrollment for the Ntrust-2 clinical trial to evaluate NKX019 cell therapy in patients with ANCA-associated vasculitis (AAV) and other autoimmune disorders.

The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.

The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.

Nkarta has dosed the first patient in both the Ntrust-1 trial (lupus nephritis) and the investigator-sponsored trial (systemic lupus erythematosus) of NKX019, with enrollment ongoing.